Funding & VC

Europe's Scale-Up Funding Gap: Six Constraints Holding Back VC

A new Intereconomics analysis identifies six supply-side constraints limiting venture capital for European scale-ups, paired with a reform agenda to close the funding gap.

By Olivia Hart

2 min read

Updated

Europe’s Scale-Up Funding Gap: Six Constraints on Venture Capital Supply and a Reform Agenda - Intereconomics | Review o
Europe’s Scale-Up Funding Gap: Six Constraints on Venture Capital Supply and a Reform Agenda - Intereconomics | Review oniki_emmert / pixabay

What's News

  • Intereconomics published an analysis titled 'Europe's Scale-Up Funding Gap: Six Constraints on Venture Capital Supply and a Reform Agenda'.
  • The study identifies six constraints on the supply side of European venture capital.
  • The authors pair the diagnosis with a reform agenda aimed at the scale-up funding stage.
  • The analysis frames the gap as a supply problem, not a shortage of founders or start-ups.
  • The source abstract does not disclose the size of the funding gap or cost estimates for the proposed reforms.

Europe's scale-up stage suffers from a structural shortage of venture capital, and a new analysis in Intereconomics | Review of European Economic Policy names six distinct constraints on the supply side of the market.

The study, titled "Europe's Scale-Up Funding Gap: Six Constraints on Venture Capital Supply and a Reform Agenda," frames the problem as one of supply rather than demand. Its core claim: European start-ups that survive the seed stage too often cannot find the larger cheques needed to grow into global competitors. The authors pair the diagnosis with a proposed reform agenda aimed at unlocking more capital at the scale-up stage.

That framing matters because it shifts the policy debate. Instead of asking why Europe produces fewer founders, the analysis asks why existing European growth companies cannot raise follow-on funding at the volumes their US peers take for granted.

What does the analysis actually identify?

The publication identifies six constraints that limit how much venture capital flows to European scale-ups. The article's title commits to that number, and its structure — constraints first, reform agenda second — signals that the authors see the funding gap as a solvable policy failure rather than an inevitable feature of a smaller market.

The source abstract does not itemise the six constraints individually, so readers should treat the count as the authors' analytical frame rather than a settled taxonomy. The full text, published by Intereconomics, carries the detail. What the title does make explicit is that every constraint sits on the supply side: the money available, not the companies asking for it.

That supply-side emphasis carries a caveat. If any of the six constraints prove weaker in practice than in theory, the reform agenda built on them weakens too. The analysis invites exactly that stress test.

Why does the scale-up stage matter?

The scale-up phase — the rounds after early venture funding, when a company expands headcount, production and markets — is where national champions are made. A funding gap here means European companies either stall, sell early to foreign buyers, or relocate to deeper capital markets.

Each outcome carries a cost that compounds over time: fewer large independent firms headquartered in Europe, and fewer of the high-productivity jobs those firms create. That is the implicit stakes behind the paper's title.

The promise of the reform agenda is therefore considerable. But the abstract gives no figures on the size of the gap, no timeline for reform, and no estimate of how much additional capital the six fixes could realistically mobilise. Those omissions define the boundary between what the analysis claims and what it has so far demonstrated.

What happens next?

The reform agenda now enters a policy conversation in which the EU has repeatedly pledged to deepen its capital markets. Whether any of the six proposed fixes survives contact with national governments, which guard their pension and insurance rules closely, will determine if the scale-up gap narrows or simply gets re-diagnosed.

Source: GN: Venture Capital

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

955 articles

Related articles

« Previous articleNext article »